|
JP2003081830A
|
|
Oxidation stress inhibitor
|
|
JP2003083977A
|
|
Method of measuring oxidation stress
|
|
GB0118517D0
|
|
Compound
|
|
KR20020097384A
|
|
A Medicament which is Effective for a Virus Having a Resistance Mutation against a Known Medicament
|
|
CN1423561A
|
|
Remedies for hepatitis C
|
|
WO0158487A1
|
|
Therapeutic and/or preventive agents for optic nerve diseases and retinal diseases
|
|
JP2001247538A
|
|
Method of producing amino acid derivative containing modified amino group and thiol group
|
|
WO0144468A1
|
|
Novel protein and gene
|
|
WO0142224A1
|
|
Carboxyamido derivatives
|
|
JP2001190283A
|
|
New peptide for mammal and polynucleotide encoding the same
|
|
JP2002095479A
|
|
Aurora 2 kinase inhibitor
|
|
JP2002095472A
|
|
Monoclonal antibody specifically reacting with md-1 molecule
|
|
JP2002068985A
|
|
Therapeutic agent for drug-induced hepatopathy
|
|
JP2002047281A
|
|
Telomerase inhibitor
|
|
JP2002047179A
|
|
Telomerase inhibitor
|
|
JP2002047187A
|
|
Telomerase inhibitor
|
|
JP2002027941A
|
|
Sweetener
|
|
JP2002000272A
|
|
Expression vector for phage display method, and its utilization
|
|
JP2001353476A
|
|
Adapter imparted with fitting, connecting and cleaning function and spray nozzle with self-cleaning function
|
|
JP2001352984A
|
|
Expression vector capable of screening cell highly expressing recombinant protein and its utilization
|
